

BIOGEN IDEC INC
 Form 4/A
 November 06, 2006

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
MATSUI CONNIE

(Last) (First) (Middle)

14 CAMBRIDGE CENTER

(Street)

CAMBIRDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC [BIIB]

3. Date of Earliest Transaction
 (Month/Day/Year)
10/12/2005

4. If Amendment, Date Original Filed(Month/Day/Year)
12/20/2005

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 EVP, Corp. Strategy and Comm.

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/12/2005		M	V Amount (A) or (D) Price	50,437.7331 (1)	D	
Common Stock	10/12/2005		S(2)	V Amount (A) or (D) Price	31,666.7331 (1)	D	
Common Stock	10/12/2005		S(2)	V Amount (A) or (D) Price	29,166.7331 (1)	D	
Common Stock	10/12/2005		S(2)	V Amount (A) or (D) Price	21,666.7331 (1)	D	
Common Stock	10/12/2005		S(2)	V Amount (A) or (D) Price	19,166.7331 (1)	D	

Edgar Filing: BIOGEN IDEC INC - Form 4/A

Common Stock	10/12/2005	S ⁽²⁾	2,500	D	\$ 36.67	16,666.7331 (1)	D
Common Stock	10/12/2005	S ⁽²⁾	5,000	D	\$ 36.74	11,666.7331 (1)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MATSUI CONNIE 14 CAMBRIDGE CENTER CAMBIRDGE, MA 02142			EVP, Corp. Strategy and Comm.	

Signatures

By: Daniel Char; For: Connie Matsui
Date: 11/06/2006

Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) In the original Form 4 and Form 4/A filed on 01/05/2006, we incorrectly overstated the amount of securities beneficially owned following the reported transaction. This error was repeated in subsequent Form 4s relating to transactions in the same stock options.

Edgar Filing: BIOGEN IDEC INC - Form 4/A

(2) Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.